Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Salarius Pharmaceuticals Inc (SLRX)

NASDAQ
Currency in USD
Disclaimer
0.4848
-0.0257(-5.04%)
Closed
After Hours
0.5106+0.0258(+5.3218%)
SLRX Scorecard
Unusual Post-Market activity
Fair Value
Unlock Value
Day's Range
0.48480.5130
52 wk Range
0.43002.3100
Prev. Close
0.5106
Open
0.5106
Day's Range
0.4848-0.513
52 wk Range
0.43-2.31
Volume
8,779
Average Vol. (3m)
117,283
1-Year Change
-73.94%
Shares Outstanding
4,314,433
Fair Value
Unlock
Dividends Payment Streak
Unlock
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell

People Also Watch

0.0521
FSRN
+6.76%
0.1055
ASTI
-0.94%
1.46
PACB
+4.29%
1.985
EVC
-0.75%
6.89
ALT
-2.13%
How do you feel today about SLRX?
Vote to see community's results!
or

Salarius Pharmaceuticals Inc Company Profile

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing effective treatments for cancers with unmet medical needs. It is developing treatments for cancers caused by dysregulated gene expression. The Company’s product portfolio includes seclidemstat, which is being studied as a potential treatment for pediatric cancers, sarcomas and other cancers with limited treatment options. The Company's pipeline consists of two primary compounds: SP-3164, a small-molecule protein degrader, and seclidemstat (SP-2577), a small-molecule inhibitor. SP-3164 is a next-generation cereblon-binding molecular glue (MG). SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold. The molecule was discovered using structure-based computational screening coupled with chemical screening.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.